TABLE 2.
Vaccination regimena | IHA resultb
|
Caco-2 cells with bound bacteria (%)c | |
---|---|---|---|
Serum | Fecal extract | ||
Nonimmunized | — | — | 92 |
pRECFA | — | — | 90 |
HG3 | 1:4 | 1:4 | 88 |
pRE4 + HG3 | 1:4 | 1:4 | 87 |
pRECFA + HG3 | 1:512 | 1:16 | 4* |
Serum pools were from mice subjected to the following immunization protocols: nonimmunized; pRECFA, mice immunized with two i.m. doses (100 μg/dose) of pRECFA (titer of 4,268); HG3, mice immunized with two p.o. doses of the HG3 strain (1010 CFU/dose) (titer of 305); pRE4 + HG3, mice immunized with two doses of pRE4 followed 2 weeks later by two booster doses with the HG3 strain (titer of 420); pRECFA + HG3, mice subjected to the primer-booster regimen, with a 2-week interval between the priming and boosting immunizations (diluted in PBS to a final titer of 4,500).
CFA/I-specific antiadhesive potencies were measured by IHA with human group A red blood cells and the ETEC 258909-3 strain. Results are maximal dilutions of serum or fecal extract samples that yielded visible inhibition of the hemagglutination reactions. —, no visible reaction.
The inhibition of adhesion of the ETEC 258909-3 strain to in vitro-cultivated Caco-2 cell monolayers was also measured. The results are expressed as percentages of Caco-2 cells with at least one attached bacterium visible under an optical microscope. All serum pools were used at a final dilution of 1:3 in d-mannose-containing PBS. Data were based on the total number of cells counted in two independent determinations. *, statistically different value (P < 0.05) compared to results obtained with serum samples from other vaccinated mouse groups.